{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:44:20Z","timestamp":1778341460989,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03524-1","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T11:03:06Z","timestamp":1677668586000},"page":"2227-2236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"55","author":[{"given":"Zhong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhiQin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-4021","authenticated-orcid":false,"given":"MeiXue","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"issue":"2","key":"3524_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","volume":"361","author":"A Rajasekaran","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV (2021) IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci 361(2):176\u2013194","journal-title":"Am J Med Sci"},{"issue":"9","key":"3524_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10157-019-01735-4","volume":"23","author":"T Moriyama","year":"2019","unstructured":"Moriyama T (2019) Clinical and histological features and therapeutic strategies for IgA nephropathy. Clin Exp Nephrol 23(9):1089\u20131099","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"3524_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN (2017) IgA Nephropathy. Clin J Am Soc Nephrol CJASN 12(4):677\u2013686","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"3","key":"3524_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40620-016-0360-z","volume":"30","author":"R Coppo","year":"2017","unstructured":"Coppo R (2017) Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol 30(3):339\u2013346","journal-title":"J Nephrol"},{"key":"3524_CR5","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney international. 2021 Oct;100(4):S1-S276."},{"issue":"1","key":"3524_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","volume":"18","author":"YH Song","year":"2017","unstructured":"Song YH, Cai GY, Xiao YF, Wang YP, Yuan BS, Xia YY et al (2017) Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol 18(1):61","journal-title":"BMC Nephrol"},{"issue":"8","key":"3524_CR7","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1177\/0300060518776566","volume":"46","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Luo J, Hu B, Ma T (2018) Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis. J Int Med Res 46(8):3236\u20133250","journal-title":"J Int Med Res"},{"issue":"7","key":"3524_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","volume":"53","author":"H Liu","year":"2014","unstructured":"Liu H, Xu X, Fang Y, Ji J, Zhang X, Yuan M et al (2014) Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial. Intern Med 53(7):675\u2013681","journal-title":"Intern Med"},{"issue":"8","key":"3524_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071545","volume":"8","author":"YC Kim","year":"2013","unstructured":"Kim YC, Chin HJ, Koo HS, Kim S (2013) Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS ONE 8(8):e71545","journal-title":"PLoS ONE"},{"issue":"12","key":"3524_CR10","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00467-011-1919-5","volume":"26","author":"O Jauhola","year":"2011","unstructured":"Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P et al (2011) Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatr Nephrol 26(12):2159\u20132166","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"3524_CR11","first-page":"127","volume":"150","author":"J Schiele","year":"1999","unstructured":"Schiele J, Nowack R, Julian BA, van der Woude FJ (1999) Treatment of immunoglobulin A nephropathy. Ann Med Intern 150(2):127\u2013136","journal-title":"Ann Med Intern"},{"issue":"3","key":"3524_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF02550423","volume":"23","author":"KN Lai","year":"1991","unstructured":"Lai KN, Lam CW, Cheng IK, Tam JS, Lai FM (1991) Effect of cyclosporine A on circulating immune complexes in IgA nephropathy. Int Urol Nephrol 23(3):265\u2013274","journal-title":"Int Urol Nephrol"},{"issue":"3 Suppl 4","key":"3524_CR13","first-page":"297","volume":"20","author":"KN Lai","year":"1988","unstructured":"Lai KN, Mac-Moune Lai F, Vallance-Owen J (1988) A short-term controlled trial of cyclosporine A in IgA nephropathy. Transpl Proc 20(3 Suppl 4):297\u2013303","journal-title":"Transpl Proc"},{"key":"3524_CR14","first-page":"253","volume":"44","author":"M Hong","year":"2016","unstructured":"Hong M, Zhang DW, Mei YM (2016) Tacrolimus combined with low-dose glucocorticoid clinical effect on patients with northern IgA nephropathy. Clin J Med Off 44:253\u2013258","journal-title":"Clin J Med Off"},{"key":"3524_CR15","first-page":"1681","volume":"11","author":"Z Li","year":"2020","unstructured":"Li Z, Wang FP (2020) Therapeutic effects of tacrolimus combined with low-dose glucocorticoid on IgA nephropathy and the changes of IL-17 and IL-23 levels. Hebei Med J 11:1681\u20131683","journal-title":"Hebei Med J"},{"issue":"25","key":"3524_CR16","first-page":"4885","volume":"15","author":"JJ Liu","year":"2015","unstructured":"Liu JJ, Huang YH, Peng YM (2015) Effect of cyclosporine combined with glucocorticoids on IgA, C3 and IgA\/C3 in patients with IgA nephropathy. Prog Modern Biomed 15(25):4885\u20134891","journal-title":"Prog Modern Biomed"},{"issue":"2","key":"3524_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","volume":"39","author":"K Knobloch","year":"2011","unstructured":"Knobloch K, Yoon U, Vogt PM (2011) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Cranio-Maxillo-Facial surg 39(2):91\u201392","journal-title":"J Cranio-Maxillo-Facial surg"},{"key":"3524_CR18","first-page":"2884","volume":"22","author":"HM Bao","year":"2016","unstructured":"Bao HM, Guo WG, Ren Z (2016) Curative effect observation of tacrolimus combined with glucocorticoid in the treatment of primary iga nephropathy with mild to moderate renal injury. Med Recaputulate 22:2884\u20132887","journal-title":"Med Recaputulate"},{"key":"3524_CR19","first-page":"31","volume":"24","author":"XH Gan","year":"2016","unstructured":"Gan XH, Wang S (2016) Efficacy and safety of tacrolimus combined with corticosteroids in the treatment of primary IgA nephropathy with mild to moderate renal impairment. J Community Med 24:31\u201332","journal-title":"J Community Med"},{"key":"3524_CR20","first-page":"16","volume":"9","author":"D Liao","year":"2013","unstructured":"Liao D, Xiao H, Jiang D (2013) Tacrolimus in treatment of refractory IgA nephropathy: a clinical observation. Chin Health Care Nutr 9:16\u201317","journal-title":"Chin Health Care Nutr"},{"issue":"18","key":"3524_CR21","first-page":"1825","volume":"31","author":"HY Ouyang","year":"2015","unstructured":"Ouyang HY (2015) Clinical efficacy and safety of cyclosporine A combined with glucocorticoid in the treatment of immunoglobulin A nephropathy with large number of protein urine. Chin J Chin Pharmacol 31(18):1825\u20131827","journal-title":"Chin J Chin Pharmacol"},{"issue":"Suppl 1","key":"3524_CR22","volume":"28","author":"P Shen","year":"2013","unstructured":"Shen P, Li Y, Wang Z, Wang W, Ren H, Zhang W (2013) A prospective randomized study on the effiicacy of corticosteroid combined with cyclophosphamide or FK506 in primary IGA nephropathy with mild or moderate renal injury. Nephro Dia Transplant 28(Suppl 1):i175","journal-title":"Nephro Dia Transplant"},{"key":"3524_CR23","first-page":"885","volume":"30","author":"PY Shen","year":"2014","unstructured":"Shen PY, Jia XY, Wang CH (2014) The treatment of tacrolimus in primary IgA nephropathy with mild or moderate renal injury: a randomized controlled study. Chin J Nehphrol 30:885\u2013890","journal-title":"Chin J Nehphrol"},{"key":"3524_CR24","first-page":"11","volume":"20","author":"YY Song","year":"2010","unstructured":"Song YY (2010) Effects of Tacrolimus (FK506) combined with low-dose glucocorticoid in the treatment of IgA Nephropathy. J Jilin Univ 20:11\u201313","journal-title":"J Jilin Univ"},{"key":"3524_CR25","first-page":"481","volume":"39","author":"QC Sun","year":"2017","unstructured":"Sun QC, Zhao HF, Li LN (2017) Clinical efficacy of low-dose tacrolimus joint glucocorticoid on IgA nephropathy with moderate proteinuria: a retrospectively trial. J Third Military Med Univ 39:481\u2013486","journal-title":"J Third Military Med Univ"},{"key":"3524_CR26","first-page":"1239","volume":"11","author":"J Tang","year":"2016","unstructured":"Tang J (2016) Efficacy of CsA combined with prednison on treatment of IgA nephropathy in children and the effects on IL-18 and ICAM-1. Med J Nat Def Forces Southwest China 11:1239\u20131241","journal-title":"Med J Nat Def Forces Southwest China"},{"key":"3524_CR27","first-page":"168","volume":"3","author":"XW Wang","year":"2017","unstructured":"Wang XW, Wang AW, Zhang QQ, Gui ZH, Hf W (2017) Research of cyclosporine A combined with union\/low-dose prednisone on the treatment of progressive IgA nephropathy. Chin J Pharmacoepidemiol 3:168\u2013170","journal-title":"Chin J Pharmacoepidemiol"},{"key":"3524_CR28","first-page":"3619","volume":"22","author":"GY Wu","year":"2015","unstructured":"Wu GY, Chen XB, Jiang XL (2015) Clinical study of tacrolimus combined with small dose of prednisolone in treatment of IgA nephropathy. Chin J Prim Med Pham 22:3619\u20133622","journal-title":"Chin J Prim Med Pham"},{"key":"3524_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.kjms.2014.04.002","volume":"30","author":"L Xu","year":"2014","unstructured":"Xu L, Liu ZC, Guan GJ (2014) Cyclosporine A combined with medium\/low dose prednisone in progressive IgA nephropathy. Kaohsiung J Med Sci 30:390\u2013395","journal-title":"Kaohsiung J Med Sci"},{"issue":"3","key":"3524_CR30","first-page":"263","volume":"23","author":"JX Zhang","year":"2013","unstructured":"Zhang JX, Qian JZ (2013) Clinical efficacy of tacrolimus combined with small does of hormone therapy on IgA nephropathy. J Jiangsu Univ 23(3):263\u2013267","journal-title":"J Jiangsu Univ"},{"issue":"3","key":"3524_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2215\/CJN.04820511","volume":"7","author":"JK Kim","year":"2012","unstructured":"Kim JK, Kim JH, Lee SC, Kang EW, Chang TI, Moon SJ et al (2012) Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol CJASN 7(3):427\u2013436","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"3","key":"3524_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10157-018-1642-7","volume":"23","author":"D Takada","year":"2019","unstructured":"Takada D, Hoshino J, Fujii T, Usui J, Fujii T, Ohashi K et al (2019) Association between renal outcome and the number of steroid pulse therapies after tonsillectomy in patients with IgA nephropathy. Clin Exp Nephrol 23(3):335\u2013341","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"3524_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/tri.13075","volume":"31","author":"N Leeaphorn","year":"2018","unstructured":"Leeaphorn N, Garg N, Khankin EV, Cardarelli F, Pavlakis M (2018) Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS\/OPTN database. Transplant Int 31(2):175\u2013186","journal-title":"Transplant Int"},{"issue":"2","key":"3524_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000188848","volume":"72","author":"Y Kobayashi","year":"1996","unstructured":"Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S (1996) Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 72(2):237\u2013242","journal-title":"Nephron"},{"key":"3524_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01530-7","author":"DNW Lie","year":"2023","unstructured":"Lie DNW, Chan KW, Tang AHN, Chan ATP, Chan GCW, Lai KN et al (2023) Long-term outcomes of add-on direct renin inhibition in igA nephropathy: a propensity score-matched cohort study. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-022-01530-7","journal-title":"J Nephrol"},{"issue":"4","key":"3524_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/157340606777724068","volume":"2","author":"DS Goumenos","year":"2006","unstructured":"Goumenos DS, Kalliakmani P, Tsakas S, Savidaki I, Vlachojannis JG (2006) Cyclosporin-A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after its administration) blood levels. Med Chem 2(4):391\u2013393","journal-title":"Med Chem"},{"issue":"4","key":"3524_CR37","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/ajkd.2001.27689","volume":"38","author":"LP Bartosik","year":"2001","unstructured":"Bartosik LP, Lajoie G, Sugar L, Cattran DC (2001) Predicting progression in IgA nephropathy. Am J Kidney Dis 38(4):728\u2013735","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3524_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000225563","volume":"30","author":"GY Cai","year":"2009","unstructured":"Cai GY, Chen XM (2009) Immunoglobulin A nephropathy in China: progress and challenges. Am J Nephrol 30(3):268\u2013273","journal-title":"Am J Nephrol"},{"issue":"3","key":"3524_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/MNH.0000000000000405","volume":"27","author":"S Barbour","year":"2018","unstructured":"Barbour S, Reich H (2018) An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens 27(3):214\u2013220","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"3524_CR40","first-page":"713","volume":"21","author":"H Arikan","year":"2008","unstructured":"Arikan H, Koc M, Cakalagaoglu F, Eren Z, Segal MS, Tuglular S et al (2008) Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol 21(5):713\u2013721","journal-title":"J Nephrol"},{"issue":"3","key":"3524_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s101570200029","volume":"6","author":"T Machiguchi","year":"2002","unstructured":"Machiguchi T, Tei M, Ono T, Kambara H (2002) Re-biopsy in a patient with IgA nephropathy showing success of treatment with cyclosporin A and angiotensin-II receptor blocker. Clin Exp Nephrol 6(3):166\u2013169","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"3524_CR42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000337175","volume":"35","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Shi SF, Zhu L, Lv JC, Liu LJ, Chen YQ et al (2012) Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. Am J Nephrol 35(4):312\u2013320","journal-title":"Am J Nephrol"},{"issue":"1","key":"3524_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1081\/JDI-100100851","volume":"22","author":"V Chabova","year":"2000","unstructured":"Chabova V, Tesar V, Zabka J, Rychlik I, Merta M, Jirsa M Jr et al (2000) Long term treatment of IgA nephropathy with cyclosporine A. Ren Fail 22(1):55\u201362","journal-title":"Ren Fail"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03524-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T17:18:52Z","timestamp":1691428732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03524-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["3524"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03524-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"10 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}